Center for Cancer and Blood Disorders

Researching Cures for Cancer and Blood Diseases


CCBD Research at Children's Hospital Colorado
State-of-the-art treatment for pediatric cancer typically includes enrollment in a clinical trial. In fact, research shows that children who participate in clinical trials have better survival rates than children who do not. That’s what makes the Research Department at the Center for Cancer and Blood Disorders (CCBD) such an important part of the hospital.

Why choose Children’s Colorado for clinical trials?

Involvement in clinical trials (studies that determine if new drugs or treatments are safe and effective) is crucial to understanding diseases and finding ways to prevent or treat them. Discoveries from our laboratories on the Anschutz Medical Campus are changing the way care is delivered for pediatric hematology, oncology and bone marrow transplants.

Here’s what makes our scientific research and clinical trials program one of the nation’s most robust:

  • Children’s Hospital Colorado is a long-standing member of the Children’s Oncology Group, and many of our physicians play leadership roles in that organization.
  • Our physicians have discovered new genes important in cancer and are using this knowledge to develop new drugs and treatment protocols that more specifically and effectively kill cancer cells. New cancer targets have been identified in brain cancer, acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
  • State-of-the art genetic testing on cancer cells is being utilized to help tailor the most appropriate therapy for individual patients.
  • The leader of our Experimental Therapeutics Program also co-founded the Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC), which often expands local trials to children and adolescents across the country.
  • Orthopedic oncologists use 3D motion-capture technology from the Center for Gait and Movement Analysis to better understand functional quality of life for orthopedic oncology patients after surgery. Their findings will improve understanding of the long-term differences between surgical approaches for bone cancer.
  • Our survivorship experts lead national studies on late-effects and outcomes to improve care for future patients.
  • Clinical research led by the Hemophilia and Thrombosis Center revolutionized the care of children with hemophilia, transitioning the focus from treatment of life-threatening and debilitating bleeding episodes to prevention of bleeding through regular home administration of clotting factors.
  • Hematology researchers identified the gene that causes grey platelet syndrome, a discovery that will now be used to set the foundation of care for newly diagnosed patients.

Changing cancer treatment through research

All of our doctors also collaborate with laboratory researchers to find new cures and better cancer treatment. In 2011-12, our team secured more than $4 million per year in external research grant funding to fund new and ongoing studies.

Benefits of our location on the Anschutz Medical Campus

  • New laboratory space on the Anschutz Medical Campus facilitates communication and ideas between researchers and clinicians.
  • Being co-located on the Anschutz Medical Campus with University of Colorado Hospital, our researchers easily collaborate with adult providers and researchers, and are well-positioned to develop new adolescent and young adult approaches.
  • As the pediatric affiliate of the University of Colorado Cancer Center, our researchers gain access to the Cancer Center’s core research facilities such as tissue banking.
  • The physician-scientists at the Center for Cancer and Blood Disorders are recognized as national leaders in basic science and clinical science research and have funding to support their research from numerous national hematology and oncology research foundations.

More information about our cancer research